Cooper University Health Care is one of only 24 sites in the United States currently treating patients with central sleep apnea (CSA) with a new implantable device to stimulate breathing. The remedē^® System, developed by medical technology company Respicardia, Inc., received FDA-approval in 2017 and is the first commercially available device to treat CSA.

“CSA is a serious breathing disorder that disrupts the normal breathing pattern during sleep and negatively affects quality of life and overall cardiovascular health,” said John A. Read more.

Cooper is one of approximately 40 sites in the United States and the only hospital in the Philadelphia region participating in a clinical trial for Boston Scientific’s WATCHMAN FLX™ device. The WATCHMAN FLX™ is the next generation of a potentially life-changing catheter-based (or non-surgically delivered) device designed to close the left atrial appendage in order to reduce the risk of stroke in certain patients with atrial fibrillation (AFib). Read more.

Cooper University Health Care has expanded its life-saving air medical transport service to the South Jersey community with the addition of a new helicopter. Cooper has been providing this vital service to residents of Burlington, Camden, Gloucester, Atlantic, Cape May, Cumberland, and Salem counties since 2010.

“As the regional leader in trauma and emergency care, the medical transport helicopters are a crucial part of our emergency medical services continuum,” said Kevin O’Dowd, JD, Co-President of Cooper University Health Care. Read more.

Cooper University Health Care recently recognized Chevron Johnson, RN, of Pennsauken, NJ, with the DAISY Award for providing exceptional nursing care. Chevron work on the Pavilion 6 Surgical Intermediate unit.

The DAISY Award, established by The DAISY Foundation, is an international program that celebrates the extraordinary care given by nurses every day. It is presented in collaboration with the American Organization of Nurse Executives. Read more.